Leavitt Partners December 1, 2022
Kristin Allen

Leavitt Partners examined publicly available resources to determine the 340B Drug Pricing Program’s (340B) impact on drug prices charged by both covered entities and pharmaceutical manufacturers. To answer these questions, Leavitt Partners undertook a comprehensive literature review of publicly available governmental reports, peer-reviewed journal articles, white papers, news articles, and other publicly available sources to identify the degree to which, and to what...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Govt Agencies, Health System / Hospital, Healthcare System, HHS, Insurance, Medicare, Pharma, Pharma / Biotech, Pricing / Spending, Provider, Survey / Study, Trends
Related Articles:
Digital Retail Platforms: The new concept of Pharma to sell directly to patients
Boosting biopharma R&D performance with a next-generation technology stack
Charting the path to patients
External innovation: Biopharma dealmaking to boost R&D productivity
Building a shared vision for pharma R&D–supplier partnerships

Share This Article